BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

Summary

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.

Timeline

Start

2025-04-01

Primary completion

2026-04-15

Completion

2026-06-15

Drugs

Indications